Wall Street Analysts Bullish on Biotech Stocks with 29% to 165% Upside Potential
Healthcare remains a cornerstone for investors seeking durable returns, with biotech firms leading innovation in life-saving therapies. Regeneron Pharmaceuticals (REGN) emerges as a standout, with Wall Street projecting a 29% to 68% upside over the next 12 months. The company's monoclonal antibody platform, including blockbuster drug Dupixent, targets high-value indications like eczema and cancer.
Biotech's resilience during economic turbulence underscores its appeal. A second unnamed contender boasts multibagger potential, with analysts forecasting 165% returns. These growth profiles offer compelling exposure to healthcare's innovation pipeline, though market volatility remains a factor.